Burning Rock Biotech (BNR) Receivables - Other (2021 - 2023)

Burning Rock Biotech has reported Receivables - Other over the past 3 years, most recently at $3.2 million for Q4 2023.

  • Quarterly results put Receivables - Other at $3.2 million for Q4 2023, down 46.19% from a year ago — trailing twelve months through Dec 2023 was $3.2 million (down 46.19% YoY), and the annual figure for FY2023 was $3.2 million, down 48.48%.
  • Receivables - Other for Q4 2023 was $3.2 million at Burning Rock Biotech, down from $5.9 million in the prior quarter.
  • Over the last five years, Receivables - Other for BNR hit a ceiling of $6.6 million in Q4 2021 and a floor of $3.2 million in Q4 2023.
  • Median Receivables - Other over the past 3 years was $5.9 million (2022), compared with a mean of $5.2 million.
  • Biggest five-year swings in Receivables - Other: dropped 11.45% in 2022 and later plummeted 46.19% in 2023.
  • Burning Rock Biotech's Receivables - Other stood at $6.6 million in 2021, then fell by 11.45% to $5.9 million in 2022, then tumbled by 46.19% to $3.2 million in 2023.
  • The last three reported values for Receivables - Other were $3.2 million (Q4 2023), $5.9 million (Q4 2022), and $6.6 million (Q4 2021) per Business Quant data.